Adalimumab is a monoclonal anti-tumor necrosis factor human antibody, considered the blockbuster drug for RA treatment, and the only one that has been compared to other different biologic (b) or target synthetic (ts) DMARDs, both in monotherapy and combination with methotrexate (MTX), in head-to-head randomized clinical trials (RCTs) with some evidence of superiority [6]. Here, TNF is linked to rheumatoid arthritis.